Outputs (11)

The use of technology in type 2 diabetes and prediabetes: a narrative review (2024)
Journal Article
Liarakos, A. L., Lim, J. Z. M., Leelarathna, L., & Wilmot, E. G. (2024). The use of technology in type 2 diabetes and prediabetes: a narrative review. Diabetologia, 67(10), 2059-2074. https://doi.org/10.1007/s00125-024-06203-7

The increasing incidence of type 2 diabetes, which represents 90% of diabetes cases globally, is a major public health concern. Improved glucose management reduces the risk of vascular complications and mortality; however, only a small proportion of... Read More about The use of technology in type 2 diabetes and prediabetes: a narrative review.

Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring (2024)
Journal Article
Klonoff, D. C., Gabbay, M., Moon, S. J., & Wilmot, E. G. (2024). Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, https://doi.org/10.1177/19322968241250357

Continuous glucose monitoring (CGM) has been shown to improve glycemic control and self-monitoring, as well as to reduce the risk of hypoglycemia. Integrated CGM (iCGM) FDA-cleared systems with published performance data are established nonadjunctive... Read More about Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring.

Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis (2024)
Journal Article
Mader, J. K., Fornengo, R., Hassoun, A., Heinemann, L., Kulzer, B., Monica, M., Nguyen, T., Sieber, J., Renard, E., Reznik, Y., Rys, P., Stozek, A., & Wilmot, E. G. (2024). Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis. Diabetes Technology and Therapeutics, 26(5), 351-362. https://doi.org/10.1089/dia.2023.0491

Background: Lipohypertrophy is a common complication in patients with diabetes receiving insulin therapy. There is a lack of consensus regarding how much lipohypertrophy affects diabetes management. Our study aimed to assess the potential correlation... Read More about Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis.

Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study (2024)
Journal Article
Liarakos, A. L., Hasan, N., Crabtree, T. S. J., Leelarathna, L., Hammond, P., Hussain, S., …Wilmot, E. G. (2024). Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study. Diabetes Research and Clinical Practice, 209, Article 111597. https://doi.org/10.1016/j.diabres.2024.111597

Aims
To evaluate real-world outcomes in people with Type 1 Diabetes (PwT1D) initiated on Omnipod DASH® Insulin Management System

Methods
Anonymized clinical data were submitted to a secure web-based tool within the National Health Service networ... Read More about Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study.

Intermittently scanned continuous glucose monitoring in adults with type 1 diabetes: A subgroup analysis from the FLASH-UK study (2023)
Journal Article
Leelarathna, L., Sutton, C. J., Evans, M. L., Neupane, S., Rayman, G., Lumley, S., …Wilmot, E. G. (2024). Intermittently scanned continuous glucose monitoring in adults with type 1 diabetes: A subgroup analysis from the FLASH-UK study. Diabetic Medicine, 41(3), Article e15249. https://doi.org/10.1111/dme.15249

Aims: The FLASH-UK trial showed lower HbA1c with intermittently scanned continuous glucose monitoring (isCGM), as compared with self monitoring of blood glucose (SMBG), in adults with type 1 diabetes and HbA1c ≥58 mmol/mol (≥7.5%). Here, we present r... Read More about Intermittently scanned continuous glucose monitoring in adults with type 1 diabetes: A subgroup analysis from the FLASH-UK study.

Estimating the cost-effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England (2023)
Journal Article
Elliott, R. A., Rogers, G., Evans, M. L., Neupane, S., Rayman, G., Lumley, S., …FLASH–UK Trial Study Group. (2024). Estimating the cost-effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England. Diabetic Medicine, 41(3), Article e15232. https://doi.org/10.1111/dme.15232

We previously showed that intermittently scanned continuous glucose monitoring (isCGM) reduces HbA1c at 24 weeks compared with self-monitoring of blood glucose with finger pricking (SMBG) in adults with type 1 diabetes and high HbA1c levels (58-97 mm... Read More about Estimating the cost-effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England.

A nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID‐19 (2023)
Journal Article
Field, B. C. T., Ruan, Y., Várnai, K. A., Davies, J., Ryder, R. E. J., Gandhi, R., …Williams, D. (2023). A nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID‐19. Diabetes, Obesity and Metabolism, 25(7), 2012-2022. https://doi.org/10.1111/dom.15076

Aims
To investigate characteristics of people hospitalized with coronavirus-disease-2019 (COVID-19) and diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS), and to identify risk factors for mortality and intensive care admission... Read More about A nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID‐19.

UK's Association of British Clinical Diabetologist's Diabetes Technology Network (ABCD-DTN): Best practice guide for hybrid closed-loop therapy (2023)
Journal Article
Griffin, T. P., Gallen, G., Hartnell, S., Crabtree, T., Holloway, M., Gibb, F. W., …Hussain, S. (2023). UK's Association of British Clinical Diabetologist's Diabetes Technology Network (ABCD-DTN): Best practice guide for hybrid closed-loop therapy. Diabetic Medicine, 41(3), Article e15078. https://doi.org/10.1111/dme.15078

This best practice guide is written with the aim of providing an overview of current hybrid closed-loop (HCL) systems in use within the United Kingdom's (UK) National Health Service (NHS) and to provide education and advice for their management on bo... Read More about UK's Association of British Clinical Diabetologist's Diabetes Technology Network (ABCD-DTN): Best practice guide for hybrid closed-loop therapy.

CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review (2022)
Journal Article
Pemberton, J. S., Wilmot, E. G., Barnard‐Kelly, K., Leelarathna, L., Oliver, N., Randell, T., …Adolfsson, P. (2023). CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review. Diabetes, Obesity and Metabolism, 25(4), 916-939. https://doi.org/10.1111/dom.14962

The National Institute for Clinical Excellence updated guidance for continuous glucose monitoring (CGM) in 2022, recommending that CGM be available to all people living with type 1 diabetes. Manufacturers can trade in the UK with Conformité Européenn... Read More about CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review.

Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice (2022)
Journal Article
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., …Battelino, T. (2023). Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocrine Reviews, 44(2), 254-280. https://doi.org/10.1210/endrev/bnac022

The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long... Read More about Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice.